Clover Biopharmaceuticals (HKSE:02197) Construction In Progress: HK$15.47 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02197 Clover Biopharmaceuticals Ltd HKSE:02197
28 GF Score
Price HK$2.37
! 3 Warning Signs
View Full Analysis

What is Clover Biopharmaceuticals Construction In Progress?

Clover Biopharmaceuticals HKSE:02197 -6.88% 28 Construction In Progress is HK$15.47 Mil as of Dec. 2025. GuruFocus rates HKSE:02197 with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

Clover Biopharmaceuticals's quarterly construction in progress declined from Dec. 2024 (HK$14.96 Mil) to Jun. 2025 (HK$0.00 Mil) but then increased from Jun. 2025 (HK$0.00 Mil) to Dec. 2025 (HK$15.47 Mil).

Clover Biopharmaceuticals's annual construction in progress declined from Dec. 2023 (HK$27.65 Mil) to Dec. 2024 (HK$14.96 Mil) but then increased from Dec. 2024 (HK$14.96 Mil) to Dec. 2025 (HK$15.47 Mil).

Clover Biopharmaceuticals Construction In Progress Historical Data

* Premium members only.

The historical data trend for Clover Biopharmaceuticals's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clover Biopharmaceuticals Construction In Progress Chart

Clover Biopharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial 39.37 49.23 27.65 14.96 15.47

Clover Biopharmaceuticals Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.65 0.00 14.96 0.00 15.47
HKSE:02197
28GF Score
Clover Biopharmaceuticals Ltd HKSE:02197
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clover Biopharmaceuticals Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of HK$15.47 Mil mean?
Clover Biopharmaceuticals (HKSE:02197) has a Construction In Progress of HK$15.47 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on Clover Biopharmaceuticals and its competitors.
Is Clover Biopharmaceuticals' Construction In Progress too high?
Clover Biopharmaceuticals' current Construction In Progress is HK$15.47 Mil. Overall, Clover Biopharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Clover Biopharmaceuticals' Construction In Progress compare to VRTX and REGN?
Clover Biopharmaceuticals' Construction In Progress of HK$15.47 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Clover Biopharmaceuticals and its competitors. Clover Biopharmaceuticals's current Construction In Progress is HK$15.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clover Biopharmaceuticals stock overvalued right now?
Clover Biopharmaceuticals (HKSE:02197) has a current Construction In Progress of HK$15.47 Mil. The current Construction In Progress is HK$15.47 Mil. Clover Biopharmaceuticals' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Clover Biopharmaceuticals (HKSE:02197), the current Construction In Progress is HK$15.47 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clover Biopharmaceuticals Business Description

Address No. 758 West Nanjing Road, Room 1901, Jing’an District, Shanghai, CHN
Clover Biopharmaceuticals Ltd is a clinical-stage biotechnology company committed to unleashing the power of vaccines to save lives and improve health around the world. The leverage the proprietary Trimer-Tag technology platform to conduct R&D for vaccines that can fulfill unmet needs, with a focus on building a respiratory vaccine franchise to reduce the burden of vaccine-preventable diseases. The Group has only one operating segment, which is the research and development, manufacturing, and commercialisation of vaccines. Geographically, the company earns revenue from Mainland China and Korea.
28GF Score

Get the complete analysis for HKSE:02197

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.37
Price